Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
About
Careers
Media Partners
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
About
Careers
Media Partners
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
Urology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Contemporary Views on Performance Indicators for Bladder Cancer Treatment
6
Mins
May 2024
Bladder cancers are classified into muscle-invasive and non-muscle-invasive, the latter accounting for 75% of cases.1 Accurate and timely…
Read more
4
Mins
21st February 2023
Unexplained Renal Impairment in a Patient With Seminoma
Testicular seminomas are the most common type of testicular germ cell tumours. It typically affects young males between the ages of 30–55 years. Because of its high sensitivity to chemotherapy and radiotherapy, these tumours have high cure rates.
3
Mins
23rd January 2023
Urinary Bladder Stone: A Late Complication of Bulking Injection
Polyacrylamide hydrogel (PAHG) Bulkamid® (Axonics, Irvine, California, USA) was introduced in Europe as a promising periurethral bulking agent for the treatment of female stress and mixed urinary incontinence in 2006.
4
Mins
12th December 2022
Interview: Christopher Chapple
EMJ spoke to Christopher Chapple about his role as Secretary General of the European Association of Urology (EAU)…
11
Mins
26th October 2022
Recent Advances in the First-Line Management of Advanced Renal Cell Carcinoma: Focus on the Role of Lenvatinib Plus Pembrolizumab Combination Treatment
As part of the 37th Annual European Association of Urology (EAU) Congress, this symposium presented key data from the CLEAR study: a Phase III randomised controlled trial evaluating lenvatinib plus pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma (RCC) in the first-line (1L) setting.
8
Mins
20th September 2022
Management of Acute and Recurrent Urinary Tract Infections Caused by Resistant Pathogens
At least 60% of females worldwide will experience at least one UTI in their lifetime.4 An array of pathogenic bacteria, both gram-negative and gram-positive, can cause the infections, although in uUTIs, Escherichia coli (E. coli) is the predominant pathogen.
9
Mins
15th August 2022
Improvements in Prostate Cancer Management: Focus on Imaging and Treatment
Imaging has a pivotal role in the staging of primary prostate cancer, as well as in determining optimal management strategies.
9
Mins
15th August 2022
Pigmentary Maculopathy in Interstitial Cystitis/Bladder Pain Syndrome Treated with Oral Pentosan Polysulfate: A Review
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic condition of unknown aetiology. Symptoms can vary but there is typically pelvic pain or discomfort perceived to be related to the urinary bladder, usually accompanied by other urinary symptoms such as the persistent urge to void or frequency.
10
Mins
15th August 2022
Advancing Patient Care in the Evolving Prostate Cancer Treatment Landscape
Prostate cancer varies at initial diagnosis and in its progression, with non-metastatic and metastatic presentations that may or may not respond to ADT (Figure 1).
Loading posts...
« Previous
1
2
3
4
5
…
22
Next »